Indivior (NASDAQ:INDV) Upgraded by RODMAN&RENSHAW to “Strong-Buy” Rating

RODMAN&RENSHAW upgraded shares of Indivior (NASDAQ:INDV) to a strong-buy rating in a research report released on Tuesday,Zacks.com reports.

A number of other research firms also recently issued reports on INDV. Piper Sandler reiterated an “overweight” rating and issued a $16.00 price objective (up previously from $15.00) on shares of Indivior in a report on Friday, October 25th. Craig Hallum lowered their price target on shares of Indivior from $20.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, October 11th. Finally, Rodman & Renshaw started coverage on shares of Indivior in a report on Tuesday. They issued a “buy” rating and a $16.00 price objective on the stock.

Indivior Stock Up 1.7 %

Indivior stock opened at $12.22 on Tuesday. Indivior has a fifty-two week low of $7.33 and a fifty-two week high of $23.22. The stock’s 50 day simple moving average is $11.72 and its two-hundred day simple moving average is $11.01.

Institutional Trading of Indivior

Several institutional investors have recently bought and sold shares of INDV. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Indivior in the fourth quarter worth approximately $56,000. China Universal Asset Management Co. Ltd. purchased a new position in Indivior in the 4th quarter worth approximately $359,000. Hennion & Walsh Asset Management Inc. purchased a new position in Indivior in the 4th quarter worth approximately $1,192,000. Geode Capital Management LLC lifted its position in Indivior by 7.7% in the 3rd quarter. Geode Capital Management LLC now owns 132,239 shares of the company’s stock valued at $1,289,000 after acquiring an additional 9,500 shares in the last quarter. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Indivior in the 3rd quarter worth $294,000. 60.33% of the stock is owned by hedge funds and other institutional investors.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.